156 related articles for article (PubMed ID: 29867154)
21. Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging.
Bakavicius A; Daniunaite K; Zukauskaite K; Barisiene M; Jarmalaite S; Jankevicius F
Clin Epigenetics; 2019 Aug; 11(1):115. PubMed ID: 31383039
[TBL] [Abstract][Full Text] [Related]
22. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
23. Role of Chronic Inflammation as a Predictor of Upstaging/Upgrading in Prostate Cancer: Finding a New Group Eligible for Active Surveillance.
Nowroozi MR; Ayati M; Amini E; Aghamiri SM; Momeni SA; Ohadian Moghadam S; Valizadeh F
Urol J; 2020 Jun; 17(4):370-373. PubMed ID: 31953833
[TBL] [Abstract][Full Text] [Related]
24. Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer.
Kovac E; Vertosick EA; Sjoberg DD; Vickers AJ; Stephenson AJ
BJU Int; 2018 Dec; 122(6):1003-1009. PubMed ID: 29802773
[TBL] [Abstract][Full Text] [Related]
25. Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients.
Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Anceschi U; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
Int Urol Nephrol; 2022 Oct; 54(10):2521-2528. PubMed ID: 35838831
[TBL] [Abstract][Full Text] [Related]
26. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
[TBL] [Abstract][Full Text] [Related]
27. Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis.
Scott S; Samaratunga H; Chabert C; Breckenridge M; Gianduzzo T
BJU Int; 2015 Oct; 116 Suppl 3():26-30. PubMed ID: 26260531
[TBL] [Abstract][Full Text] [Related]
28. Comparison of pathological and biochemical outcomes after radical prostatectomy in Korean patients with serum PSA ranges.
Lee HW; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
J Korean Med Sci; 2015 Mar; 30(3):317-22. PubMed ID: 25729256
[TBL] [Abstract][Full Text] [Related]
29. The presence of high-grade prostatic intraepithelial neoplasia or atypia on prostate biopsy does not adversely affect prostatectomy outcomes for patients otherwise eligible for active surveillance.
Pietzak EJ; Kabarriti AE; Mucksavage P; Bavaria T; Van Arsdalen K; Malkowicz SB; Wein AJ; Guzzo TJ
Urology; 2014 Dec; 84(6):1442-7. PubMed ID: 25288572
[TBL] [Abstract][Full Text] [Related]
30. [Clinically predictive factors of Gleason score upgrading in patients after radical prostatectomy].
Zuo Q; Zhang F; Huang Y; Ma LL; Lu M; Lu J
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):603-606. PubMed ID: 29263497
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade.
Fanning DM; Kay E; Fan Y; Fitzpatrick JM; Watson RW
BJU Int; 2010 Mar; 105(5):631-5. PubMed ID: 19732053
[TBL] [Abstract][Full Text] [Related]
32. Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry.
Bullock N; Simpkin A; Fowler S; Varma M; Kynaston H; Narahari K
BMC Urol; 2019 Oct; 19(1):94. PubMed ID: 31623595
[TBL] [Abstract][Full Text] [Related]
33. Perineural invasion on biopsy is associated with upstaging at radical prostatectomy in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Morash C; Bateman J; Mai KT; Belanger EC; Robertson SJ; Breau RH
Pathol Int; 2016 Nov; 66(11):629-632. PubMed ID: 27709739
[TBL] [Abstract][Full Text] [Related]
34. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
[TBL] [Abstract][Full Text] [Related]
35. Histologic upgrading in patients eligible for active surveillance on saturation biopsy.
Chung PH; Darwish OM; Roehrborn CG; Kapur P; Lotan Y
Can J Urol; 2015 Feb; 22(1):7656-60. PubMed ID: 25694015
[TBL] [Abstract][Full Text] [Related]
36. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific Antigen Density Is a Good Predictor of Upstaging and Upgrading, According to the New Grading System: The Keys We Are Seeking May Be Already in Our Pocket.
Brassetti A; Lombardo R; Emiliozzi P; Cardi A; Antonio V; Antonio I; Aldo S; Tommaso R; Alberto P; Gianluca D
Urology; 2018 Jan; 111():129-135. PubMed ID: 29032238
[TBL] [Abstract][Full Text] [Related]
38. Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance.
Busch J; Magheli A; Leva N; Ferrari M; Kramer J; Klopf C; Kempkensteffen C; Miller K; Brooks JD; Gonzalgo ML
BJU Int; 2014 Oct; 114(4):517-21. PubMed ID: 24112652
[TBL] [Abstract][Full Text] [Related]
39. The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy.
Arsov C; Becker N; Rabenalt R; Hiester A; Quentin M; Dietzel F; Antoch G; Gabbert HE; Albers P; Schimmöller L
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2061-8. PubMed ID: 26013424
[TBL] [Abstract][Full Text] [Related]
40. Preoperative Statin Use at the Time of Radical Prostatectomy Is Not Associated With Biochemical Recurrence or Pathologic Upgrading.
Lyon TD; Turner RM; Yabes JG; Woldemichael E; Davies BJ; Jacobs BL; Nelson JB
Urology; 2016 Nov; 97():153-159. PubMed ID: 27516122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
